Parasite | Eso | Sto | Cancer | ESD
001 | 101 | 201 | 301 | 401 | 501 | 601 | 701 | 801 | 901 | 1000
X-linked agammaglobulinemia ȯÀÚ¿¡¼ ¹ß°ßµÈ À§¾ÏÀÔ´Ï´Ù.
X-linked agammaglobulinemia´Â ÈçÇÏÁö ¾ÊÀº º´À¸·Î ¹Ýº¹ÀûÀÎ Æó·ÅµîÀÇ °¨¿°ÁõÀ¸·Î ´ëºÎºÐ ¼Ò¾Æ°ú¿¡¼ Áø´ÜµË´Ï´Ù. °£È¤ ¼ºÀο¡¼ Áø´ÜµÇ´Â ¿¹µµ Àִµ¥ ¿À´ÃÀÇ È¯ÀÚ´Â 4³â ÀüÀÎ 22¼¼¿¡ Áø´ÜµÇ¾î follow up ÁßÀ̾ú½À´Ï´Ù. ÃÖ±Ù º¹ºÎ ºÒÆí°¨À¸·Î ½ÃÇàÇÑ À§³»½Ã°æ¿¡¼ pyloric ringÀ» involveÇÏ´Â ÀüÁ¤ºÎ À§¾ÏÀ¸·Î Áø´ÜµÇ¾ú½À´Ï´Ù. Àúµµ óÀ½ °æÇèÇÏ´ÂÁö¶ó Âü°í¹®Çå ¼Ò°³·Î Áõ·Ê¼³¸íÀ» ´ë½ÅÇÒ±î ÇÕ´Ï´Ù (Eur J Gastroenterol Hepatol 2000;12:1033-5)
Patients with primary immunodeficiencies are at high risk for developing haematological malignancies and, to a lesser degree, carcinoma. We report a patient with ascertained X-linked agammaglobulinaemia who developed a gastric carcinoma involving the distal part of the stomach associated with chronic atrophic gastritis and intestinal metaplasia. These latter conditions are considered to be precursor conditions and the role of chronic infections is likely. Patients with X-linked agammaglobulinaemia, as with other primary immunodeficiencies, could benefit from regular gastrointestinal evaluation, leading to early diagnosis and treatment of carcinoma.
2014. 6. 4. ÀÌÁØÇà
[2023-10-8] ±¹Á¦¼Ò¾Æ°úÇÐȸ¿¡¼ ¹ßÇ¥µÈ agammaglobulinemia Áõ·Ê